Novo Nordisk A/S $NVO is Foresight Global Investors Inc.’s 10th Largest Position

Foresight Global Investors Inc. lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 31.7% during the 3rd quarter, Holdings Channel.com reports. The fund owned 165,294 shares of the company’s stock after selling 76,872 shares during the quarter. Novo Nordisk A/S makes up approximately 5.4% of Foresight Global Investors Inc.’s portfolio, making the stock its 10th largest holding. Foresight Global Investors Inc.’s holdings in Novo Nordisk A/S were worth $9,172,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in NVO. True Wealth Design LLC raised its holdings in shares of Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the last quarter. Guerra Advisors Inc bought a new stake in Novo Nordisk A/S in the 3rd quarter worth approximately $25,000. Strengthening Families & Communities LLC purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at $30,000. NewSquare Capital LLC lifted its holdings in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after buying an additional 282 shares during the period. Finally, Allianz SE boosted its stake in shares of Novo Nordisk A/S by 70.0% in the 3rd quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after buying an additional 238 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Up 1.4%

Novo Nordisk A/S stock opened at $39.02 on Friday. Novo Nordisk A/S has a 12-month low of $35.85 and a 12-month high of $89.03. The firm has a market capitalization of $174.22 billion, a price-to-earnings ratio of 11.24 and a beta of 0.73. The firm has a 50 day moving average of $51.68 and a 200 day moving average of $52.48. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 52.74%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley raised NVO to Equal Weight, reducing downside concerns from that shop and providing some support for the shares. Novo Nordisk A/S (NYSE:NVO) Raised to Equal Weight at Morgan Stanley
• Positive Sentiment: Market reaction to the FDA’s tighter scrutiny of telehealth GLP‑1 advertisers lifted NVO as investors expect larger incumbent manufacturers to benefit if smaller/telehealth competitors face limits. Novo Nordisk (NVO) Stock Jumps 3% as FDA Cracks Down on Telehealth GLP-1 Advertisers
• Neutral Sentiment: Goldman Sachs reiterated a Neutral rating on NVO, leaving the firm’s guidance unchanged and offering little directional push. The Goldman Sachs Group Reaffirms “Neutral” Rating for Novo Nordisk A/S (NYSE:NVO)
• Neutral Sentiment: Market commentary is debating Novo Nordisk’s valuation after the recent share decline; some pieces argue pessimism may be overdone while others call for catalyst clarity — this keeps near-term sentiment mixed. Novo Nordisk (NYSE:NVO) Valuation Debate Lingers As Market Awaits Catalyst Clarity
• Neutral Sentiment: Analysis pieces are questioning whether the recent selloff has priced in too much pessimism, which can attract value‑oriented buyers if fundamentals hold. Is Novo Nordisk (NYSE:NVO) Now Pricing In Too Much Pessimism After Share Price Slump
• Negative Sentiment: FDA has issued another warning letter to Novo Nordisk over an “Only One Ozempic” ad and broader GLP‑1 advertising concerns — increased regulatory scrutiny of marketing claims raises compliance risk and potential reputational damage. Novo Nordisk slammed with another FDA letter for ‘Only One Ozempic’ ad
• Negative Sentiment: Additional reporting confirms the FDA’s second warning over GLP‑1 ads, reinforcing regulatory/headline risk that could pressure sentiment and invite closer agency oversight. FDA sends Novo Nordisk 2nd warning over GLP-1 ads
• Negative Sentiment: The American Hospital Association urged HRSA to block Novo Nordisk’s new claims-data submission policy for 340B hospitals, signaling potential pushback from hospital customers and possible distribution/contracting friction. AHA urges HRSA to stop Novo Nordisk’s new claims-data submission policy on 340B hospitals from going into effect
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Novo Nordisk, which could foreshadow litigation or shareholder claims and add legal uncertainty. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO

Analysts Set New Price Targets

NVO has been the subject of a number of research reports. HSBC reiterated a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. CICC Research started coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective on the stock. TD Cowen restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday. Five analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $53.93.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.